Actively Recruiting
A Multinational, Randomized, Double-Blind Study to Evaluate the Safety and Pharmacokinetics of OMN6 with Standard Antibiotics in Hospital- or Ventilator-Acquired Pneumonia Caused by Acinetobacter Baumannii Complex
Led by Omnix Medical Ltd · Updated on 2026-09-28
54
Participants Needed
15
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a phase 2a, multinational, multicenter clinical trial to evaluate the safety, tolerability, and pharmacokinetics of OMN6 in patients with hospital-acquired bacterial pneumonia HABP or ventilator-associated bacterial pneumonia VABP caused by Acinetobacter baumannii complex ABC. This study uses a double-blind, randomized, placebo-controlled design to identify safe doses and understand how OMN6 behaves in the body. Participants receive either OMN6 or a placebo alongside standard antibiotic treatment with meropenem and colistin. OMN6 is given as three 3-hour intravenous infusions in one day at doses of 50 mg, 100 mg, or 150 mg three times daily, while background antibiotic therapy continues for 7 to 14 days. The study compares OMN6 plus antibiotics to placebo plus antibiotics in a sequential randomized manner. During the study, participants will be monitored for safety outcomes over 28 days, including adverse effects and tolerance. Pharmacokinetic measures such as maximum concentration Cmax, time to maximum concentration Tmax, area under the curve AUC, and half-life t12 of OMN6 will be assessed within one day. The trial runs from May 2026 to March 2027, with participants undergoing treatment and follow-up evaluations to gather these data.
CONDITIONS
Brief Title
A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex
Research Team
B
Bella Shusterman
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here